Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Carboplatin-Taxol-Bevacizumab Regimen

Known as: Carbo-Taxol-Avastin Regimen, carboplatin-paclitaxel-bevacizumab regimen 
A chemoimmunotherapy regimen consisting of carboplatin, paclitaxel and bevacizumab used to treat advanced stage, non-small cell lung cancer which is… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
OBJECTIVE Adding bevacizumab to cisplatin-paclitaxel for advanced cervical cancer significantly improves overall and progression… Expand
2018
2018
e17547Background: Adding to bevacizumab to chemotherapy improves progression-free survival for platinum-resistant ovarian cancer… Expand
2014
2014
2001^ Background: Factors that correlate the extent of clinical benefit with anti-VEGF therapy are poorly understood. Two phase 3… Expand
2014
2014
Resume Introduction Le bevacizumab est indique en premiere ligne dans les cancers bronchiques non a petites cellules (CBNPC) de… Expand
2011
2011
combined with other chemotherapy (CT) agents was demonstrated in AVADO and RIBBON-1. Subgroup analyses of all 3 trials suggest… Expand
2010
2010
e11503 Background: The dose and schedule of paclitaxel administration have been evolving during the last years. Weekly paclitaxel… Expand
Review
2009
Review
2009
OBJECTIVE To determine efficacy, toxicity, and survival in patients with recurrent epithelial ovarian cancer (EOC) receiving… Expand
Review
2007
Review
2007
Angiogenesis and its role in the growth and development of metastases has become a topic of increasing importance. In non‐small… Expand